Raoul S. Concepcion, MD, FACS

Articles by Raoul S. Concepcion, MD, FACS

Optimization of Genetic Testing for mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 9th 2021

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.

Sequencing Therapy for mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 9th 2021

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

Role of PSMA PET Imaging in mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 2nd 2021

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

Patient Case #2: Choosing Optimal Therapy in mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 2nd 2021

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

Treatment Options for High-Volume mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 24th 2021

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Role of Conventional Imaging vs PSMA PET in mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 24th 2021

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

Patient Case #1: Treatment Selection in mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 18th 2021

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Polling Questions: Advanced Prostate Cancer

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 18th 2021

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

May 6th 2021

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

Molecular Recurrence in Oligometastatic Prostate Cancer

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

May 6th 2021

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

May 6th 2021

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

April 29th 2021

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

April 29th 2021

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

April 22nd 2021

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

April 22nd 2021

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

Considerations for Initiating ADT After Biochemical Recurrence in Prostate Cancer 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD

April 15th 2021

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Defining PSA Nadir After Definitive Therapy in Prostate Cancer 

ByRaoul S. Concepcion, MD, FACS,Brian Helfand, MD, PhD,Munir Ghesani, MD,Judd W. Moul, MD, FACS

April 15th 2021

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 